WICKERHAM LJ and STODOLA FH |
Formation of extracellular sphingolipides by microorganisms. I. Tetraacetylphyto-sphingosine from Hansenula ciferri. |
1960 |
J. Bacteriol. |
pmid:13785002
|
SWEELEY CC |
A gas chromatographic method for sphingosine assay. |
1959 |
Biochim. Biophys. Acta |
pmid:13836072
|
BRADY RO et al. |
The enzymatic synthesis of sphingosine. II. Further studies on the mechanism of the reaction. |
1958 |
J. Biol. Chem. |
pmid:13598734
|
BRADY RO and KOVAL GJ |
The enzymatic synthesis of sphingosine. |
1958 |
J. Biol. Chem. |
pmid:13563434
|
DAWSON RM |
The reported occurrence of sphingosylphosphorylcholine in animal tissues. |
1958 |
Biochem. J. |
pmid:13522629
|
HECHT E and SHAPIRO D |
Sphingosine as an inhibitor of blood clotting. |
1957 |
Science |
pmid:13432756
|
HECHT E et al. |
Sphingosine as inhibitor of prothrombin activation with thromboplastin or with threone. |
1957 |
Am. J. Physiol. |
pmid:13424718
|
BRADY RO and BURTON RM |
Purification and properties of sphingosine. |
1956 |
J. Neurochem. |
pmid:13346370
|
HAKOMORI S and MASAMUNE H |
Chemistry and biology of lipids. XXIII. A new color reaction of sphingosine and dihydrosphingosine. |
1956 |
Tohoku J. Exp. Med. |
pmid:13371598
|
WITTENBERG JB |
The separation of sphingosine and related compounds by reversed phase partition chromatography. |
1955 |
J. Biol. Chem. |
pmid:13252037
|
ZABIN I and MEAD JF |
The biosynthesis of sphingosine. II. The utilization of methyl-labeled acetate, formate, and ethanolamine. |
1954 |
J. Biol. Chem. |
pmid:13211645
|
SPRINSON DB and COULON A |
The precursors of sphingosine in brain tissue. |
1954 |
J. Biol. Chem. |
pmid:13163042
|
ZABIN I and MEAD JF |
The biosynthesis of sphingosine. I. The utilization of carboxyl-labeled acetate. |
1953 |
J. Biol. Chem. |
pmid:13117905
|
SADHU DP |
Influence of lactose on the transglycosidation of sphingosine base in the rat brain. |
1953 |
Am. J. Physiol. |
pmid:13114397
|
HECHT E |
[A systematic study of the significance of lipoids in blood coagulation. II. The effect of the diaminophosphatides and their degradation product sphingosine]. |
1953 |
Acta Haematol. |
pmid:13064995
|
KERR WR and ROBERTSON M |
Effect of ACTH, cortisone, sphingomyelin, sphingosine and phenergan (antihistamine) in inhibiting the skin reaction in cattle sensitized to Trichomonas foetus antigen. |
1952 |
J Hyg (Lond) |
pmid:12990794
|
FISHER N et al. |
Action of sphingosine and its derivatives on tuberculin sensitivity in guineapigs. |
1951 |
Lancet |
pmid:14874428
|
CARTER HE et al. |
Biochemistry of the sphingolipides. VI. The o-methyl ethers of sphingosine. |
1951 |
J. Biol. Chem. |
pmid:14917665
|
DUBOS RJ |
The effect of sphingomyelin on the growth of tubercle bacilli. |
1948 |
J. Exp. Med. |
pmid:18871879
|
Maciejek Z et al. |
Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. |
|
Neurol. Neurochir. Pol. |
pmid:23650003
|
Yamasaki T et al. |
Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. |
|
Cell Transplant |
pmid:9710310
|
Krieger S |
Multiple sclerosis therapeutic pipeline: opportunities and challenges. |
|
Mt. Sinai J. Med. |
pmid:21425264
|
Derwenskus J |
Current disease-modifying treatment of multiple sclerosis. |
|
Mt. Sinai J. Med. |
pmid:21425262
|
Huizinga R and Voyer T |
New paradigms in immunosuppression. |
|
CANNT J |
pmid:14596200
|
Li XK et al. |
Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with Fas, Bcl-2 and Bax expression. |
|
Transplant. Proc. |
pmid:9123299
|
Li XK et al. |
FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecular ICAM-1 in TNF-alpha treated human umbilical vein endothelial cells. |
|
Transplant. Proc. |
pmid:9123298
|
Hussar DA and Zimmerman DE |
New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate. |
|
J Am Pharm Assoc (2003) |
pmid:21247838
|
Pruvost R and Le Stunff H |
[Sphingosine kinase-1: role in non alcoholic fatty liver disease]. |
|
Med Sci (Paris) |
pmid:27615179
|
Zhang Z et al. |
FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury. |
|
J. Cell. Mol. Med. |
pmid:17488479
|
Ubai T et al. |
FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. |
|
Anticancer Res. |
pmid:17352219
|
Katsel P et al. |
Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? |
|
Neurochem. Res. |
pmid:17342407
|
Harrison K |
Fingolimod for multiple sclerosis: a review for the specialist nurse. |
|
Br J Nurs |
pmid:24933548
|
Yopp AC et al. |
Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. |
|
Clin Transplant |
pmid:17100731
|
Francois M et al. |
Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis. |
|
Pharm Stat |
pmid:22888087
|
Fujino M et al. |
T-cell apoptosis triggered by FTY720 via mitochondrial pathway. |
|
Transplant. Proc. |
pmid:11750325
|
Kahan BD |
FTY720: a new dimension in transplantation. |
|
Transplant. Proc. |
pmid:11750324
|
Brinkmann V et al. |
FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. |
|
Transplant. Proc. |
pmid:11750323
|
Kelly-Laubscher RF et al. |
Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3. |
|
Cardiovasc J Afr |
pmid:25000441
|
Chen S et al. |
FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. |
|
Transplant. Proc. |
pmid:11750317
|
Huang K et al. |
Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. |
|
Int J Immunopathol Pharmacol |
pmid:22697071
|
Chun J and Hartung HP |
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. |
|
Clin Neuropharmacol |
pmid:20061941
|
Troncoso P et al. |
FTY 720 prevents ischemic reperfusion damage in rat kidneys. |
|
Transplant. Proc. |
pmid:11267102
|
Fu F et al. |
FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. |
|
Transplant. Proc. |
pmid:11267010
|
Chueh SC et al. |
FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. |
|
Transplant. Proc. |
pmid:11266948
|
Law SL et al. |
Gene transfer mediated by sphingosine/ dioleoylphosphatidylethanolamine liposomes in the presence of poloxamer 188. |
|
Drug Deliv |
pmid:16401595
|
Brinkmann V et al. |
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. |
|
Transplant. Proc. |
pmid:11266942
|
Tabasinezhad M et al. |
Sphingosin 1-phosphate contributes in tumor progression. |
|
J Cancer Res Ther |
pmid:24518696
|
|
|
|
|
pmid:
|
Tedesco-Silva H et al. |
FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. |
|
Clin Transplant |
pmid:19719728
|
Sordillo PP et al. |
Review: The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. |
|
In Vivo |
pmid:26546519
|
Sauro S et al. |
Di-Calcium Phosphate and Phytosphingosine as an Innovative Acid-Resistant Treatment to Occlude Dentine Tubules. |
|
Caries Res. |
pmid:27179116
|
Pin D et al. |
An emulsion restores the skin barrier by decreasing the skin pH and inflammation in a canine experimental model. |
|
J. Comp. Pathol. |
pmid:24975893
|
Suleiman M et al. |
FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. |
|
Transplant. Proc. |
pmid:15808648
|
Yan S et al. |
Control of intestinal allograft rejection by FTY720 and costimulation blockade. |
|
Transplant. Proc. |
pmid:15808565
|
Galvão VR et al. |
Prolonged administration of FTY720 does not cause renal toxicity in mice. |
|
Transplant. Proc. |
pmid:15808564
|
Schmid G et al. |
FTY720 inhibits tumor growth and angiogenesis. |
|
Transplant. Proc. |
pmid:15808563
|
Kataoka H et al. |
Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. |
|
Transplant. Proc. |
pmid:15808562
|
Duan RD |
Anticancer compounds and sphingolipid metabolism in the colon. |
|
In Vivo |
pmid:15796189
|
Lu W et al. |
Improved Proliferation and Differentiation of Bone Marrow Mesenchymal Stem Cells Into Vascular Endothelial Cells With Sphingosine 1-Phosphate. |
|
Transplant. Proc. |
pmid:26293094
|
Yanagawa Y et al. |
FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. |
|
Transplant. Proc. |
pmid:10083548
|
Suzuki T et al. |
Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. |
|
Transplant. Proc. |
pmid:10083540
|
Kunikata S et al. |
Immunosuppressive action of FTY720 for renal allograft a rat model. |
|
Transplant. Proc. |
pmid:10083517
|
DeAngelis T and Lublin F |
Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. |
|
Mt. Sinai J. Med. |
pmid:18500719
|